MedPath

Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS)

Phase 2
Completed
Conditions
Sarcoma, Soft Tissue
First Posted Date
2005-09-20
Last Posted Date
2007-04-20
Lead Sponsor
University Hospital Tuebingen
Registration Number
NCT00204646
Locations
🇩🇪

Medical Center II, University of Tuebingen, Tuebingen, Germany

Efficacy of G-CSF-Priming in Elderly AML Patients

Phase 4
Conditions
Acute Myeloid Leukemia
First Posted Date
2005-09-20
Last Posted Date
2005-10-26
Lead Sponsor
Johann Wolfgang Goethe University Hospital
Target Recruit Count
250
Registration Number
NCT00199147
Locations
🇩🇪

University Hospital, Medical Department II, Frankfurt, Germany

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

First Posted Date
2005-09-20
Last Posted Date
2022-08-18
Lead Sponsor
Goethe University
Target Recruit Count
1883
Registration Number
NCT00198991
Locations
🇩🇪

University of Frankfurt, Medical Dept. II, Frankfurt, Germany

Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma

Phase 2
Completed
Conditions
Neuroendocrine Carcinoma
First Posted Date
2005-09-19
Last Posted Date
2023-04-11
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
100
Registration Number
NCT00193531

Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

Phase 3
Completed
Conditions
Neoplasms, Unknown Primary
Interventions
Drug: Gemcitabine
Drug: Etoposide
Drug: Paclitaxel
Drug: Irinotecan
Drug: Carboplatin
First Posted Date
2005-09-19
Last Posted Date
2013-05-03
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
198
Registration Number
NCT00193596
Locations
🇺🇸

Tower Oncology, Beverly Hills, California, United States

🇺🇸

Clearview Cancer Institute, Huntsville, Alabama, United States

🇺🇸

Jackson Oncology Associates, Jackson, Mississippi, United States

and more 28 locations

Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma

Phase 2
Completed
Conditions
Non-Hodgkins Lymphoma
First Posted Date
2005-09-19
Last Posted Date
2011-05-03
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
40
Registration Number
NCT00193505
Locations
🇺🇸

Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

Phase 2
Completed
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: gemcitabine
Drug: cisplatin
Drug: docetaxel
Drug: etoposide
Radiation: radiation therapy
First Posted Date
2005-09-19
Last Posted Date
2010-02-17
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
64
Registration Number
NCT00191139
Locations
🇰🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Suwon-City, Korea, Republic of

Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma

Phase 2
Completed
Conditions
Retinal Neoplasms
Retinoblastoma
First Posted Date
2005-09-16
Last Posted Date
2020-08-05
Lead Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Target Recruit Count
30
Registration Number
NCT00179920
Locations
🇺🇸

Children's Memorial Hospital, Chicago, Illinois, United States

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

First Posted Date
2005-09-16
Last Posted Date
2008-04-23
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
42
Registration Number
NCT00187122
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
Drug: Etoposide
Drug: Cyclophosphamide
First Posted Date
2005-09-15
Last Posted Date
2014-05-20
Lead Sponsor
Rutgers, The State University of New Jersey
Target Recruit Count
15
Registration Number
NCT00176605
Locations
🇺🇸

UMDNJ/Robert Wood Johnson Medical School, Newark, New Jersey, United States

🇺🇸

Robert Wood Johnson University Hospital/CINJ at Hamilton, Hamilton, New Jersey, United States

🇺🇸

Morristown Memorial Hospital, Morristown, New Jersey, United States

and more 4 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy